Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.

Lee WL, Cheng MH, Tarng DC, Yang WC, Lee FK, Wang PH.

J Chin Med Assoc. 2013 Jul;76(7):365-71. doi: 10.1016/j.jcma.2013.03.010. Epub 2013 May 9. Review.

2.

Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.

Hernández E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR.

Kidney Int. 2003 Jun;63(6):2269-74.

3.

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.

Osteoporos Int. 1999;10(4):330-6. Erratum in: Osteoporos Int 1999;10(5):433.

PMID:
10692984
4.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
5.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
6.

The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

Lee WL, Cheng MH, Chao HT, Wang PH.

Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Review.

7.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.

PMID:
16735934
8.
9.

Safety assessment of raloxifene over eight years in a clinical trial setting.

Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.

Curr Med Res Opin. 2005 Sep;21(9):1441-52.

PMID:
16197663
10.

The evolution of selective estrogen receptor modulators in osteoporosis therapy.

Hadji P.

Climacteric. 2012 Dec;15(6):513-23. doi: 10.3109/13697137.2012.688079. Epub 2012 Aug 1. Review.

11.

Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.

Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR.

Ren Fail. 2005;27(2):155-61.

PMID:
15807179
12.

[Which is the better choice, estrogen or SERMs in postmenopausal women?].

Shintani M.

Clin Calcium. 2004 Oct;14(10):105-10. Review. Japanese.

PMID:
15577140
13.

Raloxifene reduces fractures in postmenopausal women with osteoporosis.

Reginster JY, Devogelaer JP.

Clin Orthop Relat Res. 2006 Feb;443:48-54. Review.

PMID:
16462425
14.

Prevention and treatment of osteoporosis in women with breast cancer.

Mincey BA, Moraghan TJ, Perez EA.

Mayo Clin Proc. 2000 Aug;75(8):821-9. Review. Erratum in: Mayo Clin Proc 2001 Jan;76(1):113.

PMID:
10943237
15.

Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.

Kastelan D, Giljevic Z, Kraljevic I, Korsic M.

Med Hypotheses. 2006;67(5):1052-3. Epub 2006 Jun 21.

PMID:
16790322
16.

Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhäuser M.

Eur Spine J. 2012 Dec;21(12):2407-17. doi: 10.1007/s00586-012-2404-y. Epub 2012 Jun 28. Review.

17.

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.

J Bone Miner Res. 2002 Jan;17(1):1-10.

18.

Selective estrogen receptor modulators in chronic renal failure.

Weisinger JR, Heilberg IP, Hernández E, Carlini R, Bellorin-Font E.

Kidney Int Suppl. 2003 Jun;(85):S62-5. Review.

PMID:
12753268
19.

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H 3rd, Gennari C, Christiansen C, Arnaud CD, Delmas PD.

Arch Intern Med. 2000 Dec 11-25;160(22):3444-50.

PMID:
11112238
20.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517

Supplemental Content

Support Center